Compare GSK plc (GSK) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Quanta Services Inc — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while Quanta Services Inc trades at $700.31 (market cap $103.03B). The key difference: GSK plc and Quanta Services Inc are close in size by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Quanta Services Inc for 62 Days on average.
| GSK | PWR | |
|---|---|---|
Market Cap | $91.88B | $103.03B |
Volume | 7,730,529 | 977,892 |
Sector | Health | Industrials |
52-Week High | $61.18 | $785.24 |
52-Week Low | $43.24 | $412.21 |
Typical Hold Time | 93 Days | 62 Days |
Enterprise Value | $111.88B | $109.13B |
Dividend Yield | 3.9% | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
PWR trades at $701.01, down slightly by 0.01% on the day, with a bullish technical signal and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is robust, climbing from $17.1B in 2022 to $28.5B in 2025, though net margins remain modest at 4.03%. A record backlog of $53B and positive news on AI infrastructure demand highlight near-term catalysts.
Outlook is positive given earnings momentum and sector tailwinds, but high valuation ratios (P/E of 78.41) and execution risks on large projects pose challenges. With 75% of analysts rating it a Buy and a consensus price target of $802.08, upside potential exists if growth sustains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
